<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Many antithrombotic drugs may have a deleterious effect on <z:mpath ids='MPATH_458'>normal</z:mpath> haemostasis leading to <z:mp ids='MP_0001914'>bleeding</z:mp> complications </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to determine if sub-therapeutic (low) doses of antithrombotic agents, when administered in combination, have enhanced efficacy without augmentation of <z:mp ids='MP_0001914'>bleeding</z:mp> time </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: The antithrombotic effects of i.v. aspirin (4-30 mg/kg), <z:chebi fb="5" ids="28304">heparin</z:chebi> (100-500 U/kg), enoxaparin (4-30 mg/kg) and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (10-20 mg/kg) were studied in a rat Folts-like preparation of carotid <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The frequency of cyclic flow reductions (CFRs; indicating occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation) and <z:mp ids='MP_0001914'>bleeding</z:mp> time were measured </plain></SENT>
<SENT sid="4" pm="."><plain>Drug doses that were singly ineffective at preventing occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation were tested in the following combinations: aspirin (10 mg/kg) with <z:chebi fb="5" ids="28304">heparin</z:chebi> (250 U/kg); aspirin (4 mg/kg) with enoxaparin (4 mg/kg); and aspirin (10 mg/kg) with <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (10 mg/kg) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Control period (pretreatment) CFRs were not significantly different between groups; average 7.0+/-0.3 CFRs/30 min (n=64) </plain></SENT>
<SENT sid="6" pm="."><plain>Tail <z:mp ids='MP_0001914'>bleeding</z:mp> time before drug(s) was 3.1+/-0.1 min (n=86) </plain></SENT>
<SENT sid="7" pm="."><plain>When administered alone, aspirin (4-30 mg/kg), <z:chebi fb="5" ids="28304">heparin</z:chebi> (250 U/kg) or enoxaparin (4 mg/kg) had no effect on CFRs or <z:mp ids='MP_0001914'>bleeding</z:mp> time </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> (500 U/kg), enoxaparin (10 and 30 mg/kg) and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (20 mg/kg) significantly decreased CFRs </plain></SENT>
<SENT sid="9" pm="."><plain>Single administration of <z:chebi fb="5" ids="28304">heparin</z:chebi> (500 U/kg) or enoxaparin (30 mg/kg) <z:hpo ids='HP_0003010'>increased bleeding time</z:hpo> by 4- or 11-fold </plain></SENT>
<SENT sid="10" pm="."><plain>When co-administered, aspirin 10 mg/kg and <z:chebi fb="5" ids="28304">heparin</z:chebi> 250 U/kg decreased CFRs, but also <z:hpo ids='HP_0003010'>increased bleeding time</z:hpo> by 11-fold </plain></SENT>
<SENT sid="11" pm="."><plain>However, combination of aspirin and enoxaparin (4 mg/kg each), or aspirin and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (10 mg/kg each), decreased CFRs with no effect on <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: In a preparation of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> in the rat, combinations of sub-efficacious (low) doses of aspirin with enoxaparin or <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> inhibited <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation without augmenting <z:mp ids='MP_0001914'>bleeding</z:mp> time </plain></SENT>
<SENT sid="13" pm="."><plain>However, low-dose aspirin combined with <z:chebi fb="5" ids="28304">heparin</z:chebi>, whilst inhibiting <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation, exacerbated <z:mp ids='MP_0001914'>bleeding</z:mp> time </plain></SENT>
<SENT sid="14" pm="."><plain>If these findings translate into the clinic, the use of effective low-dose combinations may have therapeutic advantages </plain></SENT>
</text></document>